Fathom Therapeutics Scores $47 Million Series A

Fathom Therapeutics, formerly Atommap Corp., raised an oversubscribed $47 million Series A.

Sutter Hill Ventures led the round, with Chemistry, Alexandria Venture Investments, and NY Ventures participating.

The company will use the funding to build a computational platform for designing new drug molecules.

The deal underscores continued investor interest in AI- and quantum chemistry-driven biotech tools.